ARCHIVES
VOL. 7, ISSUE 4 (2022)
A comprehensive review of thalassemia disease, current treatment and managing endocrinopathies
Authors
Saurabh Ramnarayan Dhut, Swati S Wagh, Dr. Swati Rawat, Avinash D Hatkar, Yogiraj Mule, Sunil S Jaybhaye, Sandip Phoke
Abstract
Thalassemia Is a Blood Disorder. Thalassemia is the most common form of inherited anemia worldwide. The World Health Organization reports suggest that about 60000 infants are born with a major thalassemia every year. The term “thalassemia” is derived from the Greek words “Thalassa” (sea) and “Haema” (blood) and refers to disorders associated with defective synthesis of alpha- or beta -globin subunits of hemoglobin (Hb) A (alpha-; beta), inherited as pathologic alleles of one or more of the globin genes located on chromosomes 11 (beta) and 16 (alpha). The thalassemia’s represent the most common monogenetic disorder worldwide. Because thalassemia heterozygosity confers some immunity against malaria, there is a particularly high incidence of thalassemia (2.5%-25%) in the Mediterranean basin, the Middle East, the tropical and subtropical regions of Africa, the Asian subcontinent, and Southeast Asia, where milder forms of the disease are most commonly seen. Cases of thalassemia also occur sporadically in virtually every ethnic group and geographic location. As per Act 2016 Thalassemia Is blood Disability (Include In 21 Bench Mark Disabilty)
Download
Pages:33-40
How to cite this article:
Saurabh Ramnarayan Dhut, Swati S Wagh, Dr. Swati Rawat, Avinash D Hatkar, Yogiraj Mule, Sunil S Jaybhaye, Sandip Phoke "A comprehensive review of thalassemia disease, current treatment and managing endocrinopathies". International Journal of Pharmaceutical Science and Research, Vol 7, Issue 4, 2022, Pages 33-40
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.

